思埃然医疗完成新一轮超亿元融资

Core Insights - SierraMedical, a leading domestic ophthalmic medical device innovation company, has successfully completed a new round of financing exceeding 100 million yuan, following a previous round in 2024 [1] - The financing was led by Qianji Capital and Shunwei Capital, with existing shareholders such as Boxin Capital and Honghui Fund also increasing their investments [1] - The funds will primarily be used for the in-depth research and development of the company's first self-developed phacoemulsification and vitrectomy integrated machine product line, as well as to enrich the company's ophthalmic surgical equipment product matrix [1] Company Development - SierraMedical aims to accelerate the import substitution of high-end ophthalmic instruments and the international expansion of its ophthalmic products [1] - The successful completion of this financing reflects investors' high recognition of SierraMedical's innovation capabilities and development prospects, providing strong momentum for the company's next stage of growth [1] - Established in July 2022, SierraMedical's core team possesses extensive industry experience and has complete capabilities in research, production, and commercialization [1] Industry Context - The domestic ophthalmic surgical equipment market has long relied on imported brands, but SierraMedical is gradually breaking this situation with its core proprietary technology [1] - The company focuses on providing precise and intelligent minimally invasive surgical treatment solutions for ophthalmology, aiming to break the monopoly of foreign enterprises in the high-end ophthalmic surgical instrument sector and address critical surgical instrument supply issues [1]